At the news
? NEUTRALIMPACT 3/10 CLUSTER filed Nov 12, 2026 at 16:41 ET
Three Cytokinetics insiders, including the CEO and EVP of R&D, sold a total of $824K in open-market sales over a week, all under 10b5-1 plans. The sales follow a strong Q3 2026 earnings beat and reaffirmed guidance, but the CEO's $471K sale is material relative to the $8.2B market cap (0.006%). The cluster is neutral given the small size relative to market cap and the pre-planned nature of the trades.
- CEO Blum sold 7,500 shares for $471K on 2026-11-02 under a 10b5-1 plan
- EVP Malik sold 3,500 shares for $220K on 2026-11-03 under a 10b5-1 plan
- Director Parshall sold 5,000 shares total ($273K) on 2026-11-09 under a 10b5-1 plan
- Total open-market sales: $824K, or 0.01% of $8.2B market cap
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access